Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers

Clin Liver Dis. 2023 May;27(2):251-273. doi: 10.1016/j.cld.2023.01.004. Epub 2023 Feb 26.

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses the entire spectrum of fatty liver disease in individuals without significant alcohol consumption, including isolated steatosis, steatohepatitis, and cirrhosis. The overall global prevalence of NAFLD is estimated to be 30%, and the associated clinical and economic burden will continue to increase. NAFLD is a multisystemic disease with established links to cardiovascular disease, type 2 diabetes, metabolic syndrome, chronic kidney disease, polycystic ovarian syndrome, and intra- and extrahepatic malignancies. In this article the authors review the potential mechanisms and current evidence for the association between NAFLD and extrahepatic cancers and the resultant impact on clinical outcomes.

Keywords: Cancer; Cancer outcomes; Cancer therapy; Carcinogenesis; Diabetes; Insulin resistance; Nonalcoholic fatty liver; inflammation.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / epidemiology
  • Humans
  • Liver / pathology
  • Liver Cirrhosis / epidemiology
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / metabolism
  • Metabolic Syndrome* / complications
  • Metabolic Syndrome* / epidemiology
  • Neoplasms*
  • Non-alcoholic Fatty Liver Disease* / pathology